David Z.I. Cherney - Publications, H-index & Citations

Back

David Z.I. Cherney

university health network

76H-index

563Paper Count

2.6WCitation Count

Published Papers 287

Publication Date

The Impact of Kidney Function on Diabetic Ketoacidosis and Severe Hypoglycemia Among Adults With Type 1 Diabetes: Insights From the T1D Exchange Real-World Observation Study

DIABETES OBESITY & METABOLISM

IF5.7

2026-08-11

PREAI

Tae Won Yi; Slaven Sikirica; Saketh Rompicherla; Susan Thapa; Michael Davies; Francesco Vendrame; David Lam; Nirali Shah; Guillermo Umpierrez; Osagie Ebekozien; Bruce A. Perkins; David Z. I. Cherney

Save

Effects of Vicadrostat/Empagliflozin in People With Chronic Kidney Disease: Metabolic Subgroup Analyses

diabetes, obesity and metabolism

IF0

2026-05-05

OAAI

David Z. I. Cherney; Peter Rossing; Maria Eugenia Canziani; Maria Luiza Caramori; Ricardo Correa-Rotter; Lisa Cronin; Christian Hugo; Bo Ji; Juliane Meyerhoff; Masaomi Nangaku; Arnold Silva; Dorothea Urbach; Shimoli V. Shah; Dick de Zeeuw; Katherine R. Tuttle

Save

WCN26-3792 Mechanistic Kidney Effects of Semaglutide by Baseline SGLT2i Use in Type 2 Diabetes: A Post-hoc Analysis of the REMODEL Trial

Kidney International Reports

IF5.7

2026-05-04

OAAI

David Cherney; Radica Alicic; Milenta Chacko; Lynette Driscoll; Emma Olesen; Prachi Priyadarshini; Vikas Sridhar; Katherine Tuttle; Petter Bjornstad

Save

Acute Estimated Glomerular Filtration Rate Decline After Initiation of Therapies That Slow Kidney Disease Progression: Clinical Practice Implications

Mayo Clinic Proceedings

IF6.7

2026-04-21

OAAI

David Z.I. Cherney; Radica Z. Alicic; Marc P. Bonaca

Save

Association of Ertugliflozin on Kidney Outcomes in People After and Without an Interval Cardiovascular Event: Observations From the VERTIS CV Trial

American Journal of Kidney Diseases

IF8.2

2026-04-21

PREAI

Ayodele Odutayo; Francesco Cosentino; Richard E. Pratley; Christopher P. Cannon; Chih-Chin Liu; Robert Frederich; Urszula Masiukiewicz; Nilo B. Cater; Ira Gantz; David Z.I. Cherney

Save

Renal functional reserve predicts GFR response to empagliflozin in RENALIS and RACELINES clinical trials

Nephrology Dialysis Transplantation

IF5.6

2026-04-01

PREAI

van Baar, Michael J. B.; Bjornstad, Petter; Touw, Daan J.; Joles, Jaap A.; Krebber, Merle M.; Cherney, David Z., I; van Raalte, Daniel H.; Muskiet, Marcel H. A.

Save

Semaglutide and cardiovascular risk in type 1 diabetes: A predictive modelling analysis in a double-blind, randomised, placebo-controlled cross-over trial

diabetes, obesity and metabolism

IF0

2026-02-02

OAAI

Luxcia Kugathasan PhD; Michael A. Tsoukas MD; Massimo Nardone PhD; Vikas S. Sridhar MD; Marcel H. A. Muskiet MD; David Z. I. Cherney MD; Ahmad Haidar PhD; Melissa-Rosina Pasqua MD

Save

Cardiovascular-Kidney Effects of Dapagliflozin in Patients at Cardiovascular Risk With or Without Type 2 Diabetes: Results of a Randomized, Double-Blind, Placebo-Controlled Trial

Hypertension

IF8.2

2026-02-01

PREAI

Sridhar, Vikas S.; Kugathasan, Luxcia; Lytvyn, Yuliya; Deng, Yangqing; Liu, Hongyan; Lovblom, Leif Erik; Tse, Josephine; Nardone, Massimo; Floras, John S.; Osuntokun, Tosin; Tobushi, Tomoyuki; Lam, Ruthabella C. Y.; Lam, Brian; Stevens, Jasper; Burger, Dylan; Touw, Daan J.; Heerspink, Hiddo J. L.; Lovshin, Julie A.; Perkins, Bruce A.; Cherney, David Z. I.

Save

Effects of sotagliflozin on markers of volume status and sodium handling in patients with type 1 diabetes: A biomarker analysis of the inTandem3 clinical trial

diabetes, obesity and metabolism

IF0

2026-01-27

OAAI

Massimo Nardone PhD; Erik Moedt MSc; Hiddo J. L. Heerspink PhD; Michael J. Davies PhD; Manon Girard MSc; David Z. I. Cherney MD; Marcel H. A. Muskiet MD

Save

Next-generation therapeutics for diabetic kidney disease

Nature Reviews Nephrology

IF39.8

2026-01-12

PREAI

Tae Won Yi; Vikas S. Sridhar; Jennifer Scott; Massimo Nardone; David Cherney

Save

The Role of Inflammation and High-Sensitivity C-Reactive Protein in Atherosclerotic Cardiovascular Disease and Chronic Kidney Disease: The FLAME-ASCVD Survey among Nephrologists

Cardiorenal Medicine

IF2.9

2026-01-01

OAAI

Perkovic, Vlado; Cherney, David; Erazo-Tapia, Edmundo; Gerward, Sofia; Waechter, Sandra; Sahay, Manisha; Marx, Nikolaus

Save

Chronic kidney disease screening to reduce cardiovascular risk: a call to action

American Journal of Preventive Cardiology

IF5.9

2025-12-11

OAAI

Erin D. Michos; David Cherney; Pam Kushner

Save

Efficacy, Mechanisms, and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Kidney Transplant Recipients

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

IF7.1

2025-12-01

PREAI

Sridhar, Vikas S.; Kugathasan, Luxcia; Lytvyn, Yuliya; Liu, Hongyan; Deng, Yangqing; Lovblom, Leif Erik; Nardone, Massimo; Yuen, Darren A.; Chen, Yixiao; Hua, Jonathan; Aronson, Yarden; Mohsen, Mai; Kim, S. Joseph; Udell, Jacob A.; Perkins, Bruce A.; Stevens, Jasper; Touw, Daan J.; Heerspink, Hiddo J. L.; Cherney, David Z. I.; Singh, Sunita K. S.

Save

Glucagon-like Peptide-1 Receptor Agonists and Risk of Major Adverse Cardiovascular Events in Patients With CKD

American Journal of Kidney Diseases

IF8.2

2025-11-12

OAAI

Kevin Yau; Joel G. Ray; Nivethika Jeyakumar; Bin Luo; Sheikh Abdullah; Stephanie N. Dixon; Sara Wing; Kristin K. Clemens; Fabio Castrillon-Ramirez; Jacob A. Udell; Alejandro Meraz-Munoz; Ann Young; Ziv Harel; Jeffrey Perl; Lawrence A. Leiter; Amit X. Garg; David Z.I. Cherney; Ron Wald

Save

REMODELing Mechanistic Trials for Kidney Disease: a multi-modal, tissue-centered approach to understand the renal mechanism of action of semaglutide

Kidney International

IF12.6

2025-11-07

OAAI

Menno Pruijm; Nicolas Belmar; Petter Bjornstad; David Z.I. Cherney; Vivek Das; Thomas Gunnarsson; Jeffrey B. Hodgin; Philip A. Schytz; Katherine R. Tuttle; Matthias Kretzler

Save

Amylin and the renin-angiotensin system: risk or opportunity in amylin-based therapy?

The Lancet

IF97.3

2025-11-06

PREAI

Marcel H A Muskiet; Massimo Nardone; Patrick C N Rensen; David Z I Cherney; Mark E Cooper

Save

The non-steroidal mineralocorticoid receptor blocker esaxerenone reduces glomerular hyperfiltration and albuminuria

Nephrology Dialysis Transplantation

IF5.6

2025-11-06

OAAI

Rie Tatsugawa; Kengo Kidokoro; Tsukasa Iwakura; Akira Hirano; Eriko Kajimoto; Masanobu Takasu; Masafumi Wada; Hiroshi Kitao; Yoshihisa Wada; Georgina Gyarmati; Seiji Kishi; Hajime Nagasu; David Z I Cherney; Janos Peti-peterdi; Tamaki Sasaki; Naoki Kashihara

Save

Effects of Empagliflozin on Urine Biomarkers in EMPA-KIDNEY

American Journal of Kidney Diseases

IF8.2

2025-10-31

OAAI

Greco B. Malijan; Rebecca J. Sardell; Natalie Staplin; Olivier Devuyst; Daniel Chapman; Michael Hill; Nadine Nägele; Stewart Moffat; Dilushi Wijayaratne; Killian Donovan; Doreen Zhu; Dominik Steubl; Sibylle J. Hauske; Michaela Petrini; Sarah Y.A. Ng; Roberto Pontremoli; David Z.I. Cherney; Katherine R. Tuttle; Martin J. Landray; Christoph Wanner; Colin Baigent; Michael G. Shlipak; Richard Haynes; Parminder K. Judge; Joachim H. Ix; William G. Herrington

Save

Cardiorenal outcomes and long-term kidney function decline in IgA nephropathy compared with chronic kidney disease patients with and without diabetes-FinnGen study

Nephrology Dialysis Transplantation

IF5.6

2025-10-01

OAAI

Senturk, Matti; Visser, Tomas; Pyle, Laura; Narongkiatikhun, Phoom; Bjornstad, Petter; Hellman, Tapio; Choi, Ye Ji; Cherney, David; Kiryluk, Krzysztof; Niiranen, Teemu; Finne, Patrik; Gordin, Daniel

Save

FGF-23, hsCRP, Cardiovascular Events, and the Benefit of Canagliflozin in the CANVAS Trial

JACC-ADVANCES

IF0

2025-10-01

PREAI

Punithan, Aranya; Ghamarian, Ehsan; Grothe, Daniela; Maclean, Macy; Connelly, Kim; Neal, Bruce; Weisman, Alanna; Cherney, David Z. I.; Billia, Filio; Udell, Jacob A.

Save

Research Directions